This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

43/100

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Inflammation and the immune system

Topic: Inflammation, microglia and astrocytes

Plain-language summary

In the MWM, syringin reduced escape latency. It also reduced inflammatory mRNA levels and decreased NLRP3, ASC, pro-caspase-1, and GSDMD-N protein levels. During activation, syringin suppressed cleaved caspase-1/IL-1β secretion, Iba-1 protein, transcription of microglial activation markers, LDH release, and GSDMD-N expression. Conditioned medium improved HT22 viability and reduced cleaved‑Caspase‑3. Syringin disrupted ASC-pro‑Caspase‑1 but not ASC-NLRP3 interaction, lowered ASC monomer/dimer, suppressed ROS, and restored mitochondrial potential. It inhibited SWELL1 currents. MD simulations suggested binding at key residues Tyr99 and Asp100. Syringin may inhibit SWELL1 channel in microglia, thereby limiting NLRP3 inflammasome activation and reducing neuroinflammation in AD.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Xu, Z., Huang, F., Wu, Z., Xu, K., & Huang, L. (2025). Syringin attenuates Alzheimer's disease-associated neuroinflammation by inhibiting NLRP3 inflammasome activation. Phytomedicine : international journal of phytotherapy and phytopharmacology. https://doi.org/10.1016/j.phymed.2025.157454

Vancouver

Xu Z, Huang F, Wu Z, Xu K, Huang L. Syringin attenuates Alzheimer's disease-associated neuroinflammation by inhibiting NLRP3 inflammasome activation. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2025. doi:10.1016/j.phymed.2025.157454. PMID: 41175591.

BibTeX

@article{xu2025-41175591,
  author  = {Xu, Ziwei and Huang, Feijun and Wu, Zheming and Xu, Ke and Huang, Liping},
  title   = {{Syringin attenuates Alzheimer's disease-associated neuroinflammation by inhibiting NLRP3 inflammasome activation}},
  journal = {Phytomedicine : international journal of phytotherapy and phytopharmacology},
  year    = {2025},
  doi     = {10.1016/j.phymed.2025.157454},
  pmid    = {41175591},
  url     = {https://doi.org/10.1016/j.phymed.2025.157454}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

How to read this study

Design: our record does not state a study design, so check the methods section of the original before weighing the result.
Size: the record gives no participant count. Look for one in the original before trusting a pattern.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded low. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Low means the abstract matched neither pattern. It is the default label, and it does not mean the work is poor; many sound lab and imaging papers land here. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

In the MWM, syringin reduced escape latency.
It also reduced inflammatory mRNA levels and decreased NLRP3, ASC, pro-caspase-1, and GSDMD-N protein levels.
During activation, syringin suppressed cleaved caspase-1/IL-1β secretion, Iba-1 protein, transcription of microglial activation markers, LDH release, and GSDMD-N expression.
Conditioned medium improved HT22 viability and reduced cleaved‑Caspase‑3.
Syringin disrupted ASC-pro‑Caspase‑1 but not ASC-NLRP3 interaction, lowered ASC monomer/dimer, suppressed ROS, and restored mitochondrial potential.

Study details

Evidence strengthLow

How this study scored 43/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 24 of the 56 points we could judge it on, which is 43 out of 100.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Phytomedicine : international journal of phytotherapy and phytopharmacology)
Journal's citation record	— / 4	No journal record from OpenAlex — left out of this score
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	— / 7	No citation count (not found in OpenAlex) — left out of this score
Citations per year	— / 5	No citation count or no year — left out of this score
Impact for its field and year	— / 6	No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here	— / 6	Not yet checked against this library's citation graph — left out of this score
Still being cited	— / 4	No yearly citation counts — left out of this score
Senior author's track record	— / 4	Senior author's record not available — left out of this score
Institution's track record	— / 3	No institution listed in OpenAlex — left out of this score
Multicenter collaboration	— / 3	Institutions not listed — left out of this score
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 41175591)
Free to read	— / 2	Access not recorded — left out of this score
Points	24 / 56	Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 24 of the 56 points we could judge it on is 43 out of 100.
Total	43 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Inflammation and the immune system from nearby years

Also tagged “inflammasome”

384 studies in the library carry the topic tag “inflammasome”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 384 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Inflammation and the immune system

See all studies in Inflammation and the immune system →